Q (sonnet-5.5): <conversation_so_far>
<user>
In TCGA colorectal cancer, do patients with high PTK2 expression have different survival from patients with low PTK2 expression?
</user>

<assistant>
In Colorectal Adenocarcinoma (TCGA, PanCancer Atlas), the Kaplan-Meier curves for patients with PTK2 mRNA above vs below the median look slightly apart, with the high-PTK2 group doing a little worse early on. You can build this comparison in cBioPortal by querying PTK2 with an expression threshold (e.g. `PTK2: EXP>0`) and opening the Comparison → Survival tab.
</assistant>
</conversation_so_far>

Continue this conversation: reply to the user's new message.

<user>
is the difference in survival significant?
</user>

▶ read_guide
{
 "uri": "cbioportal://statistical-tests-guide"
}

◀ result
Statistical Test Selection Guide
================================

Purpose
-------
This guide ensures the correct statistical test is selected before performing any group comparison, matching cBioPortal's own Group Comparison defaults.

HARD RULES — NEVER FABRICATE A STATISTIC
----------------------------------------
ClickHouse cannot run statistical tests. The agent therefore must NEVER produce a derived statistic that is not a literal column value from a SQL result. Specifically:

1. **Never invent a p-value.** Not "p < 0.001", not "p ≈ 0.05", not any p-value. If the user asks "what is the p-value?", the answer is *"I can't compute that — here is the 2x2 contingency table (or group statistics). Run it in cBioPortal's Group Comparison tab, in R with `fisher.test(...)` / `wilcox.test(...)`, or in Python with `scipy.stats.fisher_exact(...)` / `mannwhitneyu(...)`."*
2. **Never claim mutual exclusivity (or co-occurrence) from a contingency table alone.** A 2x2 table is not a test. The shape "altered/not altered × group A/group B" needs Fisher's exact + a defined direction (odds ratio < 1 with significant p). Without that test, the agent presents the table and stops. Descriptive phrasing is also a claim: "largely/mostly mutually exclusive", "rarely co-occur", "tend to co-occur" are forbidden without the test — point to cBioPortal's Mutual Exclusivity tab instead.
3. **Never report a "median" that came from `AVG(...)` or any non-median aggregate.** "Median" and "mean" are different statistics; for skewed clinical distributions (especially survival) they differ substantially. Use ClickHouse's `quantile(0.5)(...)` for actual median, and label arithmetic averages as "mean", never "median".
4. **Never report a hazard ratio, odds ratio, risk ratio, or relative risk** that wasn't computed by an external tool. These require regression / model fitting that ClickHouse does not do.
5. **Never report median overall survival from `AVG(OS_MONTHS)` or even `quantile(0.5)(OS_MONTHS)`.** Median OS requires Kaplan-Meier estimation, which handles censoring (`OS_STATUS = 0:LIVING` means the event hasn't happened yet). Naive medians/means over `OS_MONTHS` ignore censoring and are systematically wrong. The correct handoff: return the raw `(OS_MONTHS, OS_STATUS)` pairs (or descriptive counts: N events, N censored, follow-up range) and tell the user to run KM in R (`survival::survfit`) or Python (`lifelines.KaplanMeierFitter`), or use cBioPortal's Survival comparison.

If asked to do any of (1)–(5), respond with the appropriate handoff template from the "Approved Response Templates" section below — do not produce the number.

Ambiguous-Term Clarification (before any analysis)
--------------------------------------------------
If the user's question uses an ambiguous term, ask before computing anything. Examples:

- **"aggressive"** → could mean shorter overall survival, higher metastasis rate, higher grade/stage, higher TMB, or specific molecular features. Ask which definit … (9984 more chars)

▶ resolve_and_route
{
 "studyIds": [
  "coadread_tcga_pan_can_atlas_2018"
 ]
}

◀ result
{"success":true,"message":"Found 1 study. Use the metadata to call the appropriate navigation tool(s).","data":{"totalCount":1,"studiesWithMetadata":[{"studyId":"coadread_tcga_pan_can_atlas_2018","name":"Colorectal Adenocarcinoma (TCGA, PanCancer Atlas)","sampleCount":594,"studyViewUrl":"https://www.cbioportal.org/study?id=coadread_tcga_pan_can_atlas_2018","metadata":{"clinicalAttributeIds":["AGE","AJCC_PATHOLOGIC_TUMOR_STAGE","AJCC_STAGING_EDITION","ANEUPLOIDY_SCORE","BUFFA_HYPOXIA_SCORE","CANCER_TYPE","CANCER_TYPE_ACRONYM","CANCER_TYPE_DETAILED","DAYS_LAST_FOLLOWUP","DAYS_TO_BIRTH","DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS","DFS_MONTHS","DFS_STATUS","DSS_MONTHS","DSS_STATUS","ETHNICITY","FORM_COMPLETION_DATE","FRACTION_GENOME_ALTERED","GENETIC_ANCESTRY_LABEL","GRADE","HISTORY_NEOADJUVANT_TRTYN","ICD_10","ICD_O_3_HISTOLOGY","ICD_O_3_SITE","INFORMED_CONSENT_VERIFIED","IN_PANCANPATHWAYS_FREEZE","MSI_SCORE_MANTIS","MSI_SENSOR_SCORE","MUTATION_COUNT","NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT","ONCOTREE_CODE","OS_MONTHS","OS_STATUS","OTHER_PATIENT_ID","PATH_M_STAGE","PATH_N_STAGE","PATH_T_STAGE","PERSON_NEOPLASM_CANCER_STATUS","PFS_MONTHS","PFS_STATUS","PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT","PRIOR_DX","RACE","RADIATION_THERAPY","RAGNUM_HYPOXIA_SCORE","SAMPLE_COUNT","SAMPLE_TYPE","SEX","SOMATIC_STATUS","SUBTYPE","TBL_SCORE","TISSUE_PROSPECTIVE_COLLECTION_INDICATOR","TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR","TISSUE_SOURCE_SITE","TISSUE_SOURCE_SITE_CODE","TMB_NONSYNONYMOUS","TUMOR_TISSUE_SITE","TUMOR_TYPE","WEIGHT","WINTER_HYPOXIA_SCORE"],"molecularProfileIds":["coadread_tcga_pan_can_atlas_2018_gistic","coadread_tcga_pan_can_atlas_2018_log2CNA","coadread_tcga_pan_can_atlas_2018_mutations","coadread_tcga_pan_can_atlas_2018_protein_quantification","coadread_tcga_pan_can_atlas_2018_protein_quantification_zscores","coadread_tcga_pan_can_atlas_2018_rna_seq_v2_mrna","coadread_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_Zscores","coadread_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_all_sample_Zscores","coadread_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_all_sample_ref_normal_Zscores","coadread_tcga_pan_can_atlas_2018_rppa","coadread_tcga_pan_can_atlas_2018_rppa_Zscores","coadread_tcga_pan_can_atlas_2018_structural_variants"],"genericAssayProfiles":["coadread_tcga_pan_can_atlas_2018_armlevel_cna","coadread_tcga_pan_can_atlas_2018_genetic_ancestry","coadread_tcga_pan_can_atlas_2018_methylation_hm27_hm450_merge","coadread_tcga_pan_can_atlas_2018_methylation_hm450"],"heatmapProfileIds":["coadread_tcga_pan_can_atlas_2018_protein_quantification_zscores","coadread_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_Zscores","coadread_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_all_sample_Zscores","coadread_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_all_sample_ref_normal_Zscores","coadread_tcga_pan_can_atlas_2018_rppa_Zscores"],"availableComparisonTabs":["overlap","clinical","survival","alterations","mutations","mrna","protein","generic_assay_armlevel_c … (70 more chars)

▶ navigate_to_results_view
{
 "studyIds": [
  "coadread_tcga_pan_can_atlas_2018"
 ],
 "genes": [
  "PTK2: EXP>0"
 ],
 "tab": "comparison/survival",
 "profileFilter": "rna_seq_v2_mrna_median_Zscores"
}

◀ result
{"success":true,"message":"Navigating to https://www.cbioportal.org/results/comparison/survival?cancer_study_list=coadread_tcga_pan_can_atlas_2018&gene_list=PTK2%3A+EXP%3E0&case_set_id=coadread_tcga_pan_can_atlas_2018_all&profileFilter=rna_seq_v2_mrna_median_Zscores","url":"https://www.cbioportal.org/results/comparison/survival?cancer_study_list=coadread_tcga_pan_can_atlas_2018&gene_list=PTK2%3A+EXP%3E0&case_set_id=coadread_tcga_pan_can_atlas_2018_all&profileFilter=rna_seq_v2_mrna_median_Zscores","data":{"studyIds":["coadread_tcga_pan_can_atlas_2018"],"studies":[{"studyId":"coadread_tcga_pan_can_atlas_2018","name":"Colorectal Adenocarcinoma (TCGA, PanCancer Atlas)","sampleCount":594}],"genes":["PTK2"],"caseSetId":"coadread_tcga_pan_can_atlas_2018_all","pageDescription":"Kaplan-Meier survival analysis comparing groups defined by query genes."}}

═ answer (success)
I can't tell you whether the difference is significant, and I shouldn't have described the curves in my last message. I hadn't run the survival comparison, so I had no basis for saying the high-PTK2 group did "a little worse early on." Please disregard that. I also don't compute log-rank p-values, hazard ratios or median survival, and I won't estimate them.

A survival difference between two groups is tested with Kaplan-Meier curves and a log-rank test. cBioPortal runs that test for you and shows the p-value on the plot.

[Open the PTK2 survival comparison (TCGA colorectal, PanCancer Atlas)](https://www.cbioportal.org/results/comparison/survival?cancer_study_list=coadread_tcga_pan_can_atlas_2018&gene_list=PTK2%3A+EXP%3E0&case_set_id=coadread_tcga_pan_can_atlas_2018_all&profileFilter=rna_seq_v2_mrna_median_Zscores)

- **Groups:** The link splits patients into PTK2 z-score above 0 versus the rest.
- **Cutoff:** A z-score of 0 is not necessarily the median expression. That means it may not be an exact high-versus-low median split.
- **Results:** The page shows the log-rank p-value and the Kaplan-Meier curves for overall survival. It also has disease-free, progression-free and disease-specific survival, so you can check whether the result depends on the endpoint.
- **Confounders:** Stage and MSI status are not adjusted for, so treat any difference as unadjusted.

If you want a strict median split, I can pull each patient's PTK2 expression, overall-survival time and status. You could then run `survival::survfit` and `survdiff` in R, or `lifelines` in Python, with a cutoff you choose.